152 related articles for article (PubMed ID: 16018932)
1. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.
Kito S; Nakajima T; Koga Y
Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932
[No Abstract] [Full Text] [Related]
2. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Leo RJ; Brooks VL
Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
[TBL] [Abstract][Full Text] [Related]
3. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T
Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688
[No Abstract] [Full Text] [Related]
4. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
[TBL] [Abstract][Full Text] [Related]
5. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
[TBL] [Abstract][Full Text] [Related]
6. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
Puech A; Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
Ito M; Kimura H; Yoshida K; Kimura Y; Ozaki N; Kurita K
Clin Neuropharmacol; 2010; 33(2):79-83. PubMed ID: 20375656
[TBL] [Abstract][Full Text] [Related]
8. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
[No Abstract] [Full Text] [Related]
9. Clinical efficacy of milnacipran: placebo-controlled trials.
Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
[TBL] [Abstract][Full Text] [Related]
10. Milnacipran for the treatment of chronic pain.
Kamata M; Naito S; Takahashi H; Higuchi H
Hum Psychopharmacol; 2003 Oct; 18(7):575-6. PubMed ID: 14533142
[No Abstract] [Full Text] [Related]
11. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
12. [New drug therapy of adult attention deficit hyperactivity disorder--evaluation of efficacy of milnacipran].
Masuko H
Seishin Shinkeigaku Zasshi; 2008; 110(10):908-11. PubMed ID: 19278066
[No Abstract] [Full Text] [Related]
13. Milnacipran for fibromyalgia.
Dempsey J
Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper S; Pletan Y; Solles A; Tournoux A
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
[TBL] [Abstract][Full Text] [Related]
16. A rapid improvement in obsessive-compulsive disorder with milnacipran in a patient with schizophrenia.
Hung S; Hung GC
J Clin Psychopharmacol; 2014 Oct; 34(5):653-4. PubMed ID: 25076421
[No Abstract] [Full Text] [Related]
17. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB
Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of milnacipran: an overview.
Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
[TBL] [Abstract][Full Text] [Related]
19. Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Natelson BH; Vu D; Mao X; Weiduschat N; Togo F; Lange G; Blate M; Kang G; Coplan JD; Shungu DC
J Pain; 2015 Nov; 16(11):1211-9. PubMed ID: 26335989
[TBL] [Abstract][Full Text] [Related]
20. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]